A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Key facts
- Where
- Badalona, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Valencia, and Zaragoza, SpainSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07683065, who can take part
Where in Spain
- BadalonaBadalona, SpainTaking people
- BarcelonaBarcelona, SpainTaking people
- MadridMadrid, SpainTaking people
- MálagaMálaga, SpainTaking people
- San Cristóbal de La LagunaSan Cristóbal de La Laguna, SpainTaking people
- ValenciaValencia, SpainTaking people
- ZaragozaZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07683065
- Record updated
- 9 November 2026
- Original description
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis [PsA]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.Read full original descriptionShow less
SEC-HOPE: A Multicenter Retrospective Cohort Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis [PsA]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.
Inclusion: Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023; Patients aged ≥18 years at index date; Patients with no prior secukinumab exposure in available EMR history; Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis/psoriatic arthritis (PsA); Patients with documented administration per Summary of Product Characteristics dosing recommendations (SmPC); Patients with confirmed plaque psoriasis with or without PsA; Patients with at least one cardiometabolic risk factor; Patients with a confirmed MASLD diagnosis; Patients with baseline laboratory data available.
Exclusion: Patients with malignant liver disease; Patients with a history of liver transplantation; Patients with alcohol use disorder; Patients with other chronic liver diseases; Patients with diseases or treatments which cause thrombocytopenia; Patients with evidence of MASLD absence; Patients with decompensated cirrhosis; Other protocol-defined inclusion/exclusion criteria may apply.